Diagnosis and management of pyruvate kinase deficiency: international expert guidelines. The Lancet Haematology. 2024; 11:e228-e239.
.COVID-19 mRNA vaccination responses in individuals with sickle cell disease: an ASH RC Sickle Cell Research Network Study. Blood Advances. 2024; 8:4549-4553.
.Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial. The Lancet Haematology. 2024; 11:e425-e435.
.De Novo Brain Vascular Malformations in Hereditary Hemorrhagic Telangiectasia. Pediatric Neurology. 2024; 155:120-125.
.Brain AVM compactness score in children with hereditary hemorrhagic telangiectasia. Child's Nervous System. 2024; 40:2101-2108.
.Current Practice: Rationale for Screening Children with Hereditary Hemorrhagic Telangiectasia for Brain Vascular Malformations. American Journal of Neuroradiology. 2024; 45:1177-1184.
.Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial. Blood Advances. 2024; 8:5790-5795.
.Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study. Pediatric Blood and Cancer. 2024; 71:e30779.
.Hemoglobin concentration and body mass index are determinants of plasma von Willebrand factor and factor VIII levels. Thrombosis Research. 2024; 240:109061.
.Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity. Journal of Thrombosis and Haemostasis. 2024; 22:3191-3198.
.Emicizumab use in infancy: A survey of United States Pediatric Hemophilia Treatment Center Medical Directors. Haemophilia. 2024; 30:848-851.
.2024; 3:1331485.
. Case report: Childhood erythrocytosis due to hypermanganesemia caused by homozygous SLC30A10 mutation.Successes and pitfalls in orphan drug development for sickle cell disease. Blood Advances. 2024; 8:2455-2465.
.How we use angiopoietin-2 in the diagnosis and management of vascular anomalies. Pediatric Blood and Cancer. 2024; 71:e30921.
.Bivalirudin Monitoring in Pediatric Ventricular Assist Device and Extracorporeal Membrane Oxygenation: Analysis of Single-Center Retrospective Cohort Data 2018-2022. Pediatric Critical Care Medicine. 2024; 25:e328-e337.
.Prevalence and Predictors of Hereditary Hemorrhagic Telangiectasia and Capillary-Malformation Arteriovenous Malformation Syndrome Among Children with Neurovascular Malformations. The Journal of Pediatrics. 2024; 264:113761.
.The key roles of thrombin and fibrinogen in human infant and mice atopic dermatitis models. Allergy: European Journal of Allergy and Clinical Immunology. 2024; 79:239-242.
.Medical Management of Nonmalignant Vascular Tumors of the Head and Neck: Part 1. Oral and Maxillofacial Surgery Clinics of North America. 2024; 36:103-113.
.Medical Management and Therapeutic Updates on Vascular Anomalies of the Head and Neck: Part 2. Oral and Maxillofacial Surgery Clinics of North America. 2024; 36:115-123.
.Capillary malformations. The Journal of Clinical Investigation. 2024; 134:e172842.
.Loss of TBC1D2B causes a progressive neurological disorder with gingival overgrowth. European Journal of Human Genetics. 2024; 32:558-566.
.Hereditary hemorrhagic telangiectasia - pediatric review. Current Opinion in Pediatrics. 2024; 36:592-598.
.Unmasking the Impact of Oxygenator-Induced Hypocapnia on Blood Lactate in Veno-Arterial Extracorporeal Membrane Oxygenation. ASAIO Journal. 2024; 70:795-802.
.Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation. Journal of Thoracic and Cardiovascular Surgery. 2024; 168:e37-e53.
.Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia. Blood Advances. 2024; 8:5529-5538.
.2024; 2:120-134.
. Longitudinal prospective study of Sturge–Weber syndrome urine angiogenic factors and neurological outcome.Red cell abnormalities characterized by ektacytometry in children with cholestasis. Pediatric Research. 2024; 95:1035-1040.
.Pancytopenia in the Emergency Department. The Journal of Pediatrics. 2024; 272:114111.
.Development of a multimodal geomarker pipeline to assess the impact of social, economic, and environmental factors on pediatric health outcomes. Journal of the American Medical Informatics Association : JAMIA. 2024; 31:1471-1478.
.Evaluation, analysis, and reporting of medication adherence for clinical trials of anticoagulants in children: guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis. 2024; 22:2081-2092.
.A Mixed-Methods Evaluation of a Project ECHO Program for the Evidence-Based Management of Sickle Cell Disease. International Journal of Environmental Research and Public Health. 2024; 21:530.
.Thrombotic risk associated with gender-affirming hormone therapy. Journal of Thrombosis and Haemostasis. 2024; 22:2129-2139.
.Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024; 143:1425-1428.
.Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia. Gene Therapy (Basingstoke). 2024; 31:273-284.
.Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Clinical Pharmacology and Therapeutics. 2024; 116:670-677.
.Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. American Journal of Hematology. 2024; 99:625-632.
.Medical Therapeutics for the Treatment of Vascular Anomalies: Part 3. Oral and Maxillofacial Surgery Clinics of North America. 2024; 36:125-136.
.A pharmacokinetic-pharmacodynamic analysis of l-glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy. British Journal of Haematology. 2024; 205:1147-1158.
.A Population Pharmacokinetic Analysis of L-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects. Clinical Pharmacokinetics. 2024; 63:357-365.
.Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. Blood Advances. 2024; 8:4459-4475.
.Seeing haemoglobin SC: Challenging the misperceptions. British Journal of Haematology. 2024; 205:404-405.
.Rapid measurement of hemoglobin-oxygen dissociation by leveraging Bohr effect and Soret band bathochromic shift. The Analyst. 2024; 149:2561-2572.
.2024; 1.
. A health equity ECHO for clinicians of individuals with SCD.Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology. 2024; 46:e305-e312.
.Screening for haemoglobin disorders: One size may not fit all. British Journal of Haematology. 2024; 204:26-28.
.2024; 1:100001.
. Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy.An Institutional Approach to Equity and Improvement in Child Health Outcomes. Pediatrics. 2024; 154:e2023064994.
.The bold promise of gene therapy for sickle cell disease. British Journal of Haematology. 2024; 204:381-382.
.